-
公开(公告)号:US08106040B2
公开(公告)日:2012-01-31
申请号:US11902925
申请日:2007-09-26
申请人: Shen Gao , Daniel A. Moros , Satish Asotra
发明人: Shen Gao , Daniel A. Moros , Satish Asotra
IPC分类号: A61K31/43 , A61K31/545 , A61K31/424
CPC分类号: A61K31/43 , A61K9/0095 , A61K31/424 , A61K45/06 , A61K2300/00
摘要: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
摘要翻译: 本发明涉及改进的液体抗生素制剂。 在一些实施方案中,本发明涉及包含含有甘油三酸酯的液体中的抗生素的组合物,其中所述组合物具有小于约5%的水(w / v)。
-
公开(公告)号:US07981435B2
公开(公告)日:2011-07-19
申请号:US12779205
申请日:2010-05-13
申请人: Satish Asotra , Zoltan Bodor , Xiaoli Wang
发明人: Satish Asotra , Zoltan Bodor , Xiaoli Wang
IPC分类号: A61K9/00
CPC分类号: A61K47/38 , A61K9/0095 , A61K47/02 , A61K47/10
摘要: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.
摘要翻译: 本发明涉及包含作为药物成分的弱碱或弱酸,液体碱,粘土和水溶性纤维素醚的新型防溢剂制剂。 粘土和纤维素醚允许药物活性剂可以分散或溶解的更宽的pH范围,因此允许更容易地制备和配制药物组合物。
-
公开(公告)号:US20080076749A1
公开(公告)日:2008-03-27
申请号:US11902925
申请日:2007-09-26
申请人: Shen Gao , Daniel Moros , Satish Asotra
发明人: Shen Gao , Daniel Moros , Satish Asotra
IPC分类号: A61K31/397 , A61K31/424 , A61K31/43 , A61K31/545 , A61K47/00 , A61P43/00
CPC分类号: A61K31/43 , A61K9/0095 , A61K31/424 , A61K45/06 , A61K2300/00
摘要: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
摘要翻译: 本发明涉及改进的液体抗生素制剂。 在一些实施方案中,本发明涉及包含含有甘油三酸酯的液体中的抗生素的组合物,其中所述组合物具有小于约5%的水(w / v)。
-
公开(公告)号:US20120238534A1
公开(公告)日:2012-09-20
申请号:US13483273
申请日:2012-05-30
申请人: Satish ASOTRA , Shen Gao , Avraham Yacobi
发明人: Satish ASOTRA , Shen Gao , Avraham Yacobi
IPC分类号: A61K31/573 , A61P5/00 , A61P29/00 , A61P17/00 , A61P25/00 , A61P1/00 , A61P7/00 , A61P35/00 , A61P7/10 , C07J5/00 , A61P37/08
CPC分类号: A61K9/0053 , A61K9/0095 , A61K9/10 , A61K31/57
摘要: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
摘要翻译: 本发明涉及含有醋酸泼尼松龙,药学上可接受的载体和增稠剂的新型口服悬浮液制剂。 本发明还提供了一种用新型制剂治疗需要泼尼松龙的患者的方法。
-
公开(公告)号:US07758877B2
公开(公告)日:2010-07-20
申请号:US11049310
申请日:2005-02-02
申请人: Satish Asotra , Shen Gao , Xiaoli Wang
发明人: Satish Asotra , Shen Gao , Xiaoli Wang
IPC分类号: A61K31/55 , A61K31/473 , A61K9/00
CPC分类号: A61K9/0095 , A61K31/473 , A61K31/55 , A61K47/32 , A61K2300/00
摘要: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.
摘要翻译: 本发明提供了具有药学有效量的抗组胺剂的用于口服给药的储存稳定的药用液体悬浮液。 储存稳定的悬浮液优选含有氯雷他定。 本发明进一步提供了制备储存稳定的药物液体悬浮液的方法以及在稳定的药物液体悬液中用治疗有效量的氯雷他定治疗哺乳动物的方法。
-
公开(公告)号:US20050175642A1
公开(公告)日:2005-08-11
申请号:US11049310
申请日:2005-02-02
申请人: Satish Asotra , Shen Gao , Xaoli Wang
发明人: Satish Asotra , Shen Gao , Xaoli Wang
IPC分类号: A61K9/00 , A61K31/473 , A61K31/55 , A61K47/32
CPC分类号: A61K9/0095 , A61K31/473 , A61K31/55 , A61K47/32 , A61K2300/00
摘要: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.
摘要翻译: 本发明提供了具有药学有效量的抗组胺剂的用于口服给药的储存稳定的药用液体悬浮液。 储存稳定的悬浮液优选含有氯雷他定。 本发明进一步提供了制备储存稳定的药物液体悬浮液的方法以及在稳定的药物液体悬液中用治疗有效量的氯雷他定治疗哺乳动物的方法。
-
公开(公告)号:US08206727B2
公开(公告)日:2012-06-26
申请号:US12870144
申请日:2010-08-27
申请人: Satish Asotra , Shen Gao , Avraham Yacobi
发明人: Satish Asotra , Shen Gao , Avraham Yacobi
IPC分类号: A61K31/573 , A61P11/00 , A61P5/00 , A61P17/00 , A61P35/00
CPC分类号: A61K9/0053 , A61K9/0095 , A61K9/10 , A61K31/57
摘要: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
摘要翻译: 本发明涉及包含醋酸泼尼松龙,药学上可接受的载体和增稠剂的新型口服悬浮液制剂。 本发明还提供了一种用新型制剂治疗需要泼尼松龙的患者的方法。
-
公开(公告)号:US20120065182A1
公开(公告)日:2012-03-15
申请号:US13299829
申请日:2011-11-18
申请人: Shen GAO , Daniel A. Moros , Satish Asotra
发明人: Shen GAO , Daniel A. Moros , Satish Asotra
IPC分类号: A61K31/43 , A61P31/04 , A61K31/431
CPC分类号: A61K31/43 , A61K9/0095 , A61K31/424 , A61K45/06 , A61K2300/00
摘要: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
摘要翻译: 本发明涉及改进的液体抗生素制剂。 在一些实施方案中,本发明涉及包含含有甘油三酸酯的液体中的抗生素的组合物,其中所述组合物具有小于约5%的水(w / v)。
-
公开(公告)号:US20100324007A1
公开(公告)日:2010-12-23
申请号:US12870144
申请日:2010-08-27
申请人: Satish ASOTRA , Shen Gao , Avraham Yacobi
发明人: Satish ASOTRA , Shen Gao , Avraham Yacobi
IPC分类号: A61K31/573 , A61P11/00 , A61P5/00 , A61P17/00 , A61P35/00
CPC分类号: A61K9/0053 , A61K9/0095 , A61K9/10 , A61K31/57
摘要: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
摘要翻译: 本发明涉及包含醋酸泼尼松龙,药学上可接受的载体和增稠剂的新型口服悬浮液制剂。 本发明还提供了一种用新型制剂治疗需要泼尼松龙的患者的方法。
-
公开(公告)号:US20100261748A1
公开(公告)日:2010-10-14
申请号:US12823230
申请日:2010-06-25
申请人: Satish ASOTRA , Shen Gao , Xiaoli Wang
发明人: Satish ASOTRA , Shen Gao , Xiaoli Wang
IPC分类号: A61K31/435 , A61P27/14
CPC分类号: A61K9/0095 , A61K31/473 , A61K31/55 , A61K47/32 , A61K2300/00
摘要: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.
摘要翻译: 本发明提供了具有药学有效量的抗组胺剂的用于口服给药的储存稳定的药用液体悬浮液。 储存稳定的悬浮液优选含有氯雷他定。 本发明进一步提供了制备储存稳定的药物液体悬浮液的方法以及在稳定的药物液体悬液中用治疗有效量的氯雷他定治疗哺乳动物的方法。
-
-
-
-
-
-
-
-
-